Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials

  • Sola, Susana de
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Sánchez Benavides, Gonzalo
  • Benejam, Bessy|||0000-0002-6789-8615
  • Cuenca-Royo, Aida|||0000-0001-8551-5457
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Rodríguez, Joan
  • Catuara-Solarz, Silvina
  • Sánchez-Gutiérrez, Judit
  • Dueñas-Espin, Ivan
  • Hernandez, Gimena|||0000-0001-5319-3465
  • Peña-Casanova, J. (Jordi)|||0000-0003-1019-1536
  • Langohr, Klaus|||0000-0001-7075-9192
  • Videla, Sebastián|||0000-0001-5049-1379
  • Blehaut, Henry
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Dierssen, Mara|||0000-0003-0853-6865
Abstract: The recent prospect of pharmaceutical interventions for cognitive impairment of Down syndrome (DS) has boosted a number of clinical trials in this population. However, running the trials has raised some methodological challenges and questioned the prevailing methodology used to evaluate cognitive functioning of DS individuals. This is usually achieved by comparing DS individuals to matched healthy controls of the same mental age. We propose a new tool, the TESDAD Battery that uses comparison with age-matched typically developed adults. This is an advantageous method for probing the clinical efficacy of DS therapies, allowing the interpretation and prediction of functional outcomes in clinical trials. In our DS population the TESDAD battery permitted a quantitative assessment of cognitive defects, which indicated language dysfunction and deficits in executive function, as the most important contributors to other cognitive and adaptive behavior outcomes as predictors of functional change in DS. Concretely, auditory comprehension and functional academics showed the highest potential as end-point measures of therapeutic intervention for clinical trials: the former as a cognitive key target for therapeutic intervention, and the latter as a primary functional outcome measure of clinical efficacy. Our results also emphasize the need to explore the modulating effects of IQ, gender and age on cognitive enhancing treatments. Noticeably, women performed significantly better than men of the same age and IQ in most cognitive tests, with the most consistent differences occurring in memory and executive functioning and negative trends rarely emerged on quality of life linked to the effect of age after adjusting for IQ and gender. In sum, the TESDAD battery is a useful neurocognitive tool for probing the clinical efficacy of experimental therapies in interventional studies in the DS population suggesting that age-matched controls are advantageous for determining normalization of DS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB and Serotonin 5-HT Receptors

  • Viñals, Xavier
  • Moreno, Estefanía|||0000-0002-2491-5753
  • Lanfumey, Laurence
  • Cordomí Montoya, Arnau|||0000-0002-3848-2928
  • Pastor, Antoni|||0000-0003-3692-0696
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Gasperini, Paola
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
  • Howell, Lesley A.
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
  • Lluís, Carme
  • Canela, Enric I.|||0000-0003-4992-7440
  • McCormick, Peter J.
  • Maldonado, Rafael|||0000-0002-4359-8773
  • Robledo, Patricia
Activation of cannabinoid CB1 receptors (CBR) by delta9-tetrahydrocannabinol (THC) produces a variety of negative effects with major consequences in cannabis users that constitute important drawbacks for the use of cannabinoids as therapeutic agents. For this reason, there is a tremendous medical interest in harnessing the beneficial effects of THC. Behavioral studies carried out in mice lacking 5-HT receptors (5-HTR) revealed a remarkable 5-HTR-dependent dissociation in the beneficial antinociceptive effects of THC and its detrimental amnesic properties. We found that specific effects of THC such as memory deficits, anxiolytic-like effects, and social interaction are under the control of 5-HTR, but its acute hypolocomotor, hypothermic, anxiogenic, and antinociceptive effects are not. In biochemical studies, we show that CBR and 5-HTR form heteromers that are expressed and functionally active in specific brain regions involved in memory impairment. Remarkably, our functional data shows that costimulation of both receptors by agonists reduces cell signaling, antagonist binding to one receptor blocks signaling of the interacting receptor, and heteromer formation leads to a switch in G-protein coupling for 5-HTR from Gq to Gi proteins. Synthetic peptides with the sequence of transmembrane helices 5 and 6 of CBR, fused to a cell-penetrating peptide, were able to disrupt receptor heteromerization in vivo, leading to a selective abrogation of memory impairments caused by exposure to THC. These data reveal a novel molecular mechanism for the functional interaction between CBR and 5-HTR mediating cognitive impairment. CBR-5-HTR heteromers are thus good targets to dissociate the cognitive deficits induced by THC from its beneficial antinociceptive properties. Specific subtypes of cannabinoid and serotonin receptors interact to form heterodimers that mediate the cognitive deficits-but not the analgesic effects-induced by tetrahydrocannabinol, the major psychoactive constituent in Cannabis sativa. Delta-9-tetrahydrocannabinol (THC), the main psychoactive compound of marijuana, induces numerous undesirable effects, including memory impairments, anxiety, and dependence. Conversely, THC also has potentially therapeutic effects, including analgesia, muscle relaxation, and neuroprotection. However, the mechanisms that dissociate these responses are still not known. Using mice lacking the serotonin receptor 5-HT, we revealed that the analgesic and amnesic effects of THC are independent of each other: while amnesia induced by THC disappears in the mutant mice, THC can still promote analgesia in these animals. In subsequent molecular studies, we showed that in specific brain regions involved in memory formation, the receptors for THC and the 5-HT receptors work together by physically interacting with each other. Experimentally interfering with this interaction prevented the memory deficits induced by THC, but not its analgesic properties. Our results highlight a novel mechanism by which the beneficial analgesic properties of THC can be dissociated from its cognitive side effects.